通过多药理学靶向癌症激酶组。
Targeting the cancer kinome through polypharmacology.
机构信息
Zachary A. Knight is at The Rockefeller University, New York, New York 10065, USA.
出版信息
Nat Rev Cancer. 2010 Feb;10(2):130-7. doi: 10.1038/nrc2787.
Abstract
Kinase inhibitors are the largest class of new cancer drugs. However, it is already apparent that most tumours can escape from the inhibition of any single kinase. If it is necessary to inhibit multiple kinases, how do we choose which ones? In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.
摘要
激酶抑制剂是最大的一类新型抗癌药物。然而，大多数肿瘤显然可以逃避任何单一激酶的抑制。如果需要抑制多个激酶，我们应该如何选择？在这篇观点文章中，我们讨论了目前用于确定新的激酶靶标治疗组合的一些策略。
相似文献
1
Targeting the cancer kinome through polypharmacology.通过多药理学靶向癌症激酶组。
Nat Rev Cancer. 2010 Feb;10(2):130-7. doi: 10.1038/nrc2787.
2
Targeting cancer with small molecule kinase inhibitors.用小分子激酶抑制剂靶向治疗癌症。
Nat Rev Cancer. 2009 Jan;9(1):28-39. doi: 10.1038/nrc2559.
3
The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective.从药物-靶点相互作用网络角度看FDA批准的多靶点药物和联合产品所靶向的人类激酶组：一项比较研究
PLoS One. 2016 Nov 9;11(11):e0165737. doi: 10.1371/journal.pone.0165737. eCollection 2016.
4
Targeting multiple kinase pathways: a change in paradigm.靶向多种激酶通路：范式的转变。
Clin Cancer Res. 2010 Apr 1;16(7):1973-8. doi: 10.1158/1078-0432.CCR-09-3182. Epub 2010 Mar 9.
5
Trends in kinase drug discovery: targets, indications and inhibitor design.激酶药物研发趋势：靶点、适应症和抑制剂设计。
Nat Rev Drug Discov. 2021 Nov;20(11):839-861. doi: 10.1038/s41573-021-00252-y. Epub 2021 Aug 5.
6
Targeting cancer with kinase inhibitors.用激酶抑制剂靶向治疗癌症。
J Clin Invest. 2015 May;125(5):1780-9. doi: 10.1172/JCI76094. Epub 2015 May 1.
7
Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.人非小细胞肺癌中表皮生长因子受体-酪氨酸激酶抑制剂获得性耐药的当前机制及更新的治疗策略
J Cancer Res Ther. 2016 Dec;12(Supplement):C131-C137. doi: 10.4103/0973-1482.200613.
8
Kinase drug discovery 20 years after imatinib: progress and future directions.伊马替尼发现 20 年后的激酶药物研发：进展与未来方向
Nat Rev Drug Discov. 2021 Jul;20(7):551-569. doi: 10.1038/s41573-021-00195-4. Epub 2021 May 17.
9
Combining kinase inhibitors for optimally co-targeting cancer and drug escape by exploitation of drug target promiscuities.联合使用激酶抑制剂，通过药物靶点的混杂性来优化靶向癌症和药物逃逸。
Drug Dev Res. 2021 Feb;82(1):133-142. doi: 10.1002/ddr.21738. Epub 2020 Sep 15.
10
Small molecule inhibitors of protein kinases in cancer- how to overcome resistance.癌症中蛋白激酶的小分子抑制剂——如何克服耐药性
Mini Rev Med Chem. 2006 Oct;6(10):1101-10. doi: 10.2174/138955706778560184.
引用本文的文献
1
Polypharmacology-Driven Discovery of ZAK-I-57: A Potent Multi-Targeted Benzoxazinone Small Molecule for Hepatocellular Carcinoma Therapy.基于多药理学的ZAK-I-57发现：一种用于肝细胞癌治疗的强效多靶点苯并恶嗪酮小分子
MedComm (2020). 2025 Jul 27;6(8):e70291. doi: 10.1002/mco2.70291. eCollection 2025 Aug.
2
AI-Driven Polypharmacology in Small-Molecule Drug Discovery.小分子药物发现中的人工智能驱动多药理学
Int J Mol Sci. 2025 Jul 21;26(14):6996. doi: 10.3390/ijms26146996.
3
Sphingosine simultaneously inhibits nuclear import and activates PP2A by binding importins and PPP2R1A.鞘氨醇通过结合输入蛋白和PPP2R1A同时抑制核输入并激活PP2A。
EMBO J. 2025 Jun 30. doi: 10.1038/s44318-025-00490-5.
4
MADSP: predicting anti-cancer drug synergy through multi-source integration and attention-based representation learning.MADSP：通过多源整合和基于注意力的表征学习预测抗癌药物协同作用
Bioinformatics. 2025 Jun 2;41(6). doi: 10.1093/bioinformatics/btaf326.
5
High-Risk Neuroblastoma Stage 4 (NBS4): Developing a Medicinal Chemistry Multi-Target Drug Approach.高危神经母细胞瘤4期（NBS4）：开发一种药物化学多靶点药物方法。
Molecules. 2025 May 19;30(10):2211. doi: 10.3390/molecules30102211.
6
Dyr726, a brain-penetrant inhibitor of PI3Kα, Type III receptor tyrosine kinases, and WNT signaling.Dyr726，一种可穿透血脑屏障的PI3Kα、III型受体酪氨酸激酶和WNT信号通路抑制剂。
bioRxiv. 2025 Mar 29:2025.03.26.645490. doi: 10.1101/2025.03.26.645490.
7
New Promising Steroidal Aromatase Inhibitors with Multi-Target Action on Estrogen and Androgen Receptors for Breast Cancer Treatment.新型有前景的甾体芳香酶抑制剂对雌激素和雄激素受体具有多靶点作用，用于乳腺癌治疗。
Cancers (Basel). 2025 Jan 7;17(2):165. doi: 10.3390/cancers17020165.
8
Discovery of Thioether-Cyclized Macrocyclic Covalent Inhibitors by mRNA Display.通过 mRNA 展示发现硫醚环化的大环共价抑制剂。
J Am Chem Soc. 2024 Aug 28;146(34):24053-24060. doi: 10.1021/jacs.4c07851. Epub 2024 Aug 13.
9
Design of a covalent protein-protein interaction inhibitor of SRPKs to suppress angiogenesis and invasion of cancer cells.设计一种SRPKs的共价蛋白质-蛋白质相互作用抑制剂以抑制癌细胞的血管生成和侵袭。
Commun Chem. 2024 Jun 27;7(1):144. doi: 10.1038/s42004-024-01230-2.
10
Systematic Investigation of Dual-Target-Directed Ligands.双靶导向配体的系统研究。
J Med Chem. 2024 Jun 27;67(12):10374-10385. doi: 10.1021/acs.jmedchem.4c00838. Epub 2024 Jun 6.
本文引用的文献
1
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.AP24534是一种用于治疗慢性髓性白血病的泛BCR-ABL抑制剂，能有效抑制T315I突变体并克服基于突变的耐药性。
Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028.
2
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.系统性RNA干扰显示，致癌性KRAS驱动的癌症需要TBK1。
Nature. 2009 Nov 5;462(7269):108-12. doi: 10.1038/nature08460. Epub 2009 Oct 21.
3
Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma.肺腺癌小鼠模型中NF-κB信号传导的需求
Nature. 2009 Nov 5;462(7269):104-7. doi: 10.1038/nature08462. Epub 2009 Oct 21.
4
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.一项全基因组RNA干扰筛选鉴定出了与Ras癌基因的多种合成致死相互作用。
Cell. 2009 May 29;137(5):835-48. doi: 10.1016/j.cell.2009.05.006.
5
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.致癌性KRAS依赖性与人类癌细胞中STK33抑制之间的合成致死相互作用。
Cell. 2009 May 29;137(5):821-34. doi: 10.1016/j.cell.2009.03.017.
6
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.不依赖配体的HER2/HER3/PI3K复合物被曲妥珠单抗破坏，并被PI3K抑制剂GDC-0941有效抑制。
Cancer Cell. 2009 May 5;15(5):429-40. doi: 10.1016/j.ccr.2009.03.020.
7
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.PI3K通路激活介导KRAS突变型癌症对MEK抑制剂的耐药性。
Cancer Res. 2009 May 15;69(10):4286-93. doi: 10.1158/0008-5472.CAN-08-4765. Epub 2009 Apr 28.
8
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.一项索拉非尼联合卡铂和紫杉醇作为不可切除的III期或IV期黑色素瘤患者二线治疗的III期随机安慰剂对照研究结果。
J Clin Oncol. 2009 Jun 10;27(17):2823-30. doi: 10.1200/JCO.2007.15.7636. Epub 2009 Apr 6.
9
Challenges and opportunities in defining the essential cancer kinome.定义必需癌症激酶组中的挑战与机遇。
Sci Signal. 2009 Mar 24;2(63):pe15. doi: 10.1126/scisignal.263pe15.
10
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.转移性结直肠癌的化疗、贝伐单抗和西妥昔单抗
N Engl J Med. 2009 Feb 5;360(6):563-72. doi: 10.1056/NEJMoa0808268.
Zotero 插件